Toggle light / dark theme

Revolutionary tool will meet future pandemics with accelerated response.

A new tool speeds up development of vaccines and other pharmaceutical products by more than one million times while minimizing costs.

In search of pharmaceutical agents such as new vaccines, industry will routinely scan thousands of related candidate molecules. A novel technique allows this to take place on the nano scale, minimizing use of materials and energy. The work is published in the prestigious journal Nature Chemistry.

COLORADO SPRINGS – Lockheed Martin on April 4 released the technical specifications of a docking adapter that could be used by manufacturers to make satellites interoperable and easier to update on orbit with new technology.

The technical data for the Mission Augmentation Port (MAP) can be used by designers to develop their own docking adapters, said Lockheed Martin.

The company used the MAP standard to design its own docking device, called Augmentation System Port Interface (ASPIN).

Scientists at The University of Texas at Austin have redesigned a key component of a widely used CRISPR-based gene-editing tool, called Cas9, to be thousands of times less likely to target the wrong stretch of DNA while remaining just as efficient as the original version, making it potentially much safer.

Other labs have redesigned Cas9 to reduce off-target interactions, but so far, all these versions improve accuracy by sacrificing speed. SuperFi-Cas9, as this new version has been dubbed, is 4,000 times less likely to cut off-target sites but just as fast as naturally occurring Cas9. Bravo says you can think of the different lab-generated versions of Cas9 as different models of self-driving cars. Most models are really safe, but they have a top speed of 10 miles per hour.

“They’re safer than the naturally occurring Cas9, but it comes at a big cost: They’re going extremely slowly,” said Bravo. “SuperFi-Cas9 is like a self-driving car that has been engineered to be extremely safe, but it can still go at full speed.”

Physics World Stories podcast, Andrew Glester catches up with two engineers from the UK Atomic Energy Authority to learn more about this latest development. Leah Morgan, a physicist-turned-engineer explains why JET’s recent success is great news for the ITER project – a larger experimental fusion reactor currently under construction in Cadarache, France. Later in the episode, mechanical design engineer Helena Livesey talks about the important role of robotics for accessing equipment within the extreme conditions inside a tokamak device.

The research project took place during the heating period spanning November 2021 to April 2021 and the cooling period from May 2021 to October 2021. The PV system was designed to cover 4.9% of the roof surface area. The total installed power of the building was 480 kW.

Through their simulation, the scientists found that the shade effect of PV panels may reduce the building’s cooling demand by 10.87%, which means a lower power consumption of 136.6 kWh for the cooling months. “Conversely, PV panels increased the heating load in the winter by 3.8%, which means that the rise in heating loads in heating months was 175.3%,” they also explained. “A rooftop PV system provides a greater understanding of the heating, ventilation, and air conditioning (HVAC) energy demand variance in buildings which is critical in modern architecture.

Musk’s shareholding is more than four times the 2.25% stake held by Twitter founder Jack Dorsey.

According to a 13G filing published today, Tesla CEO Elon Musk now owns 9.2 percent of Twitter, Bloomberg News reports. Musk purchased the stock on March 14th, according to the filing. Musk has long been a high-profile Twitter user, and he recently questioned his over 80 million followers on the platform’s commitment to free speech. Twitter’s stock price rose more than 25% in pre-market trading as a result of the announcement.

According to CNBC, Musk’s Twitter stocks were worth $2.89 billion based on Friday’s closing price. Although Musk’s shares are categorized as a passive investment, Wedbush analyst Dan Ives told CNBC that the purchase “could lead to some sort of buyout.”

Macrophages travel through our arteries, gobbling fat the way Pac-man gobbled ghosts. But fat-filled macrophages can narrow blood vessels and cause heart disease. Now, UConn Health researchers describe in Nature Cardiovascular Research how deleting a protein could prevent this and potentially prevent heart attacks and strokes in humans.

Macrophages are large white blood cells that cruise through our body as a kind of clean-up crew, clearing hazardous debris. But in people with atherosclerosis—fatty deposits and inflammation in their blood vessels— macrophages can cause trouble. They eat excess fat inside artery walls, but that fat causes them to become foamy. And foamy macrophages tend to encourage inflammation in the arteries and sometimes bust apart plaques, freeing clots that can cause heart attack, stroke, or embolisms elsewhere in the body.

Changing how macrophages express a certain protein could prevent that kind of bad behavior, reports a team of researchers from UConn Health. They found that the protein, called TRPM2, is activated by inflammation. It signals macrophages to start eating fat. Since inflammation of the blood vessels is one of the primary causes of atherosclerosis, TRPM2 gets activated quite a bit. All that TRPM2 activation pushes macrophage activity, which leads to more foamy macrophages and potentially more inflamed arteries. The way that TRPM2 activated macrophage activity was surprising, says Lixia Yue, a UConn School of Medicine cell biologist.